Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia

Figures & data

Table 1 Demographics and baseline characteristics of subjects

Characteristics	Total N = 53
Age, mean (SD) years	49.96 (7.88)
Male, n (%)	38 (71.7)
Body mass index, mean (SD) kg/m^2	23.53 (3.35)
Duration of diagnosis HIV, median (range) month	93 (13–240)
Duration of efavirenz, mean (SD) month	71.09 (40.74)
Backbone regimen
Tenofovir + emtricitabine, n (%)	45 (84.90)
Tenofovir+ lamivudine, n (%)	4 (7.55)
Zidovudine+ lamivudine, n (%)	3 (5.66)
Zidovudine+ didanosine, n (%)	1 (1.89)
Nadir CD4, median (range), N = 52
Absolute CD4, cells/μL	46.0 (2–464)
%CD4	4.4 (0–22)
Current CD4, median (range)
Absolute CD4, cells/μL	514.0 (129–1562)
%CD4	22.8 (4–37)
Coronary heart disease risks, n (%)
Current smoking	7 (13.21)
Diabetes mellitus	9 (16.98)
Hypertension	15 (28.30)
Current lipid lowering agent, n (%)
None	16 (30.19)
Simvastatin	20 (37.74)
Atorvastatin	3 (5.66)
Rosuvastatin	1 (1.89)
Gemfibrozil	6 (11.32)
Fenofibrate	2 (3.77)
Simvastatin plus fenofibrate	5 (9.43)

Table 2 Mean change in fasting lipid parameters from baseline

Lipid profiles (mg/dL)	N = 53; mean (SD)
	Baseline	Week 12	Change from baseline (95%CI)	P value	Week 24	Change from baseline (95% CI)	P value
Total cholesterol	210.38 (36.87)	180.38 (38.28)	−30.00 (−36.99 to −23.01)	<0.0001	182.32 (39.22)	−28.06 (−35.20 to −20.91)	<0.0001
LDL-cholesterol	145.47 (36.37)	121.60 (36.07)	−23.87 (−30.50 to −17.24)	<0.0001	124.51 (40.39)	−20.96 (−28.12 to −13.80)	<0.0001
HDL-cholesterol	52.55 (12.16)	45.91 (11.08)	−6.64 (−9.20 to −4.09)	<0.0001	47.43 (11.01)	−5.11 (−7.79 to −2.44)	<0.0001
Triglycerides	179.42 (88.46)	143.19 (61.92)	−36.22 (−56.81 to −15.65)	0.001	149.62 (61.79)	−29.79 (−52.39 to −7.19)	0.011
Cholesterol/HDL	4.17 (1.05)	4.06 (0.94)	−0.10 (−0.32 to 0.11)	0.35	3.98 (0.98)	−0.19 (−0.39 to 0.01)	0.07

Figure 1 Change in levels of lipid profiles from baseline through to week 24